Beam Therapeutics Inc (BEAM) reported a Q3 2025 loss of $1.10 per share, falling short of the $1.06 consensus estimate. Revenue remained at $0.0 billion, matching expectations but indicating no growth. This performance reflects ongoing challenges for the biotechnology firm, which is headquartered in Cambridge, Massachusetts and focuses on precision genetic medicines, including treatments for sickle cell disease and alpha-1 antitrypsin deficiency.
The company's suite of gene editing technologies is anchored by base editing, designed to enable precise changes at targeted genomic sequences without double-stranded breaks in DNA. Beam Therapeutics employs 483 full-time workers and went public on February 6, 2020.
The company plans to host an earnings conference call to discuss these results and provide additional insights into its business performance. Investors may wish to review the full earnings release for context on the quarter's results and future outlook. Upcoming earnings are scheduled for May 3, 2026, with an EPS estimate of -1.2011 and revenue also expected at $0.0 billion.